BioNTech (NASDAQ:BNTX) Price Target Cut to $101.00

BioNTech (NASDAQ:BNTX) had its target price dropped by equities researchers at UBS Group from $110.00 to $101.00 in a research note issued on Wednesday, Benzinga reports. The brokerage currently has a “neutral” rating on the stock. UBS Group’s price objective points to a potential upside of 8.73% from the company’s previous close.

A number of other brokerages have also weighed in on BNTX. HC Wainwright dropped their price objective on BioNTech from $133.00 to $107.00 and set a “buy” rating on the stock in a report on Tuesday, January 23rd. BMO Capital Markets reduced their target price on BioNTech from $127.00 to $123.00 and set an “outperform” rating on the stock in a research report on Thursday, March 21st. JPMorgan Chase & Co. dropped their price target on BioNTech from $99.00 to $90.00 and set an “underweight” rating for the company in a research note on Friday, March 22nd. The Goldman Sachs Group dropped their price target on BioNTech from $113.00 to $100.00 and set a “neutral” rating for the company in a research note on Wednesday, February 28th. Finally, Oppenheimer started coverage on BioNTech in a research report on Friday, January 5th. They issued a “market perform” rating for the company. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and five have given a buy rating to the company. According to MarketBeat, BioNTech presently has an average rating of “Hold” and a consensus target price of $138.07.

BioNTech Stock Up 1.3 %

Shares of BNTX traded up $1.19 during midday trading on Wednesday, hitting $92.89. The company had a trading volume of 263,446 shares, compared to its average volume of 695,108. The company’s 50-day simple moving average is $93.61 and its 200-day simple moving average is $99.63. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.26 and a current ratio of 9.43. The firm has a market capitalization of $22.08 billion, a P/E ratio of 22.55 and a beta of 0.23. BioNTech has a 1 year low of $85.21 and a 1 year high of $131.52.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in BNTX. Captrust Financial Advisors raised its holdings in shares of BioNTech by 6.9% during the second quarter. Captrust Financial Advisors now owns 1,068 shares of the company’s stock valued at $159,000 after purchasing an additional 69 shares during the period. Centaurus Financial Inc. raised its stake in shares of BioNTech by 5.2% during the first quarter. Centaurus Financial Inc. now owns 1,448 shares of the company’s stock valued at $247,000 after acquiring an additional 71 shares during the last quarter. Pathstone Family Office LLC raised its stake in shares of BioNTech by 4.9% during the fourth quarter. Pathstone Family Office LLC now owns 2,205 shares of the company’s stock valued at $331,000 after acquiring an additional 103 shares during the last quarter. Cary Street Partners Investment Advisory LLC raised its stake in shares of BioNTech by 6.9% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 1,711 shares of the company’s stock valued at $186,000 after acquiring an additional 111 shares during the last quarter. Finally, Sectoral Asset Management Inc. grew its holdings in BioNTech by 3.5% in the third quarter. Sectoral Asset Management Inc. now owns 3,445 shares of the company’s stock worth $374,000 after purchasing an additional 116 shares during the period. 15.52% of the stock is currently owned by institutional investors and hedge funds.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.